COMMUNIQUÉS West-GlobeNewswire

Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
30/05/2024
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May 30, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today [...]
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
30/05/2024
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
30/05/2024
Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www.inventivapharma.com Date Nombre de titres composant le capital en circulation Nombre total [...]
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
30/05/2024
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule [...]
Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
30/05/2024
Daix (France), Long Island City (New York, Etats-Unis), le 30 mai 2024 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de petites molécules [...]
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
30/05/2024
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera [...]
Merus N.V. annonce une offre publique de souscription d’actions ordinaires
30/05/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 30 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie au stade clinique [...]
Nicox annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant maximum d’environ 3,8 millions d’euros
30/05/2024
Communiqué de presse Nicox annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant maximum d’environ 3,8 millions d’euros pour poursuivre le [...]
Merus Announces Pricing of Upsized Public Offering of Common Shares
30/05/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length [...]
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
30/05/2024
- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE [...]
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
30/05/2024
TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified [...]
CloudMD Announces Resumption of Trading on TSXV and Provides Additional Transaction Details
29/05/2024
TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, Frankfurt: 6PH) (the “ Company ” or “ CloudMD ”), an innovative health services company transforming the delivery of care, is [...]
Tarsus to Participate in Upcoming Investor Conferences
29/05/2024
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
29/05/2024
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
29/05/2024
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
29/05/2024
Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR [...]
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference
29/05/2024
BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global [...]
L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024
29/05/2024
NEW YORK, 29 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
29/05/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Pages